JOBEN BIO-MEDICAL CO., LTD.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
1. Supercritical Fluid Extraction (SFE) Technology Platform
2. Patent and herbal new botanical drug development
3. Antrodia cinnamomea product development
4. Accredited inspection body
2. Patent and herbal new botanical drug development
3. Antrodia cinnamomea product development
4. Accredited inspection body
The content above was translated by Ai
Founded Year
2010
Unified Business No.
29184631
Status
Active
Number of Employees
0
Total Paid-in
Capital
676,159,700 (NT$)
Location of Company
Taiwan
, Pingtung County
Exit Status
Emerging Stock Exchange(2015)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
By using our core technologies on natural Chinese herbal medicine, Joben Bio-Medical has successfully developed the new botanic drug JBM-TC4 (patent protection pending), which was approved by U.S. FDA-Phase II for clinical trial in March 2013, and approved by TFDA for phase II clinical trial in May When the new botanic drug JBM-TC4 is successfully developed, it will offer cancer patients all over the world more options for treating cancer effectively. A botanic drug with compound ingredients can be used with the small molecule drug of a single ingredient, and this will be a major trend for the integrated treatment of cancer in the future, for it not only can assist and increase the anti-cancer treatment, but also reduce the side effects brought about by the small molecule drug of a single ingredient. This is very significant, for it increases the living quality of the cancer patients by reducing the side effects of treatment.
Our R&D teams fully use the present core technologies and original materials to develop new botanic drugs according to the schedule of our new biotech drugs project. In July 2013, Joben Bio-Medical was approved by MOEA to be a biotech new drug company.
Our R&D teams fully use the present core technologies and original materials to develop new botanic drugs according to the schedule of our new biotech drugs project. In July 2013, Joben Bio-Medical was approved by MOEA to be a biotech new drug company.
The content above was translated by Ai
